CytRx Cash on Hand 2010-2022 | CYTR

CytRx cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
CytRx Annual Cash on Hand
(Millions of US $)
2021 $7
2020 $10
2019 $16
2018 $21
2017 $37
2016 $57
2015 $57
2014 $78
2013 $39
2012 $38
2011 $36
2010 $34
2009 $33
CytRx Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $5
2021-12-31 $7
2021-09-30 $16
2021-06-30 $8
2021-03-31 $9
2020-12-31 $10
2020-09-30 $13
2020-06-30 $15
2020-03-31 $15
2019-12-31 $16
2019-09-30 $19
2019-06-30 $19
2019-03-31 $20
2018-12-31 $21
2018-09-30 $25
2018-06-30 $36
2018-03-31 $35
2017-12-31 $37
2017-09-30 $46
2017-06-30 $55
2017-03-31 $48
2016-12-31 $57
2016-09-30 $59
2016-06-30 $56
2016-03-31 $68
2015-12-31 $57
2015-09-30 $71
2015-06-30 $54
2015-03-31 $65
2014-12-31 $78
2014-09-30 $90
2014-06-30 $102
2014-03-31 $113
2013-12-31 $39
2013-09-30 $23
2013-06-30 $28
2013-03-31 $32
2012-12-31 $38
2012-09-30 $22
2012-06-30 $27
2012-03-31 $32
2011-12-31 $36
2011-09-30 $42
2011-06-30 $26
2011-03-31 $30
2010-12-31 $34
2010-09-30 $40
2010-06-30 $42
2010-03-31 $33
2009-12-31 $33
2009-09-30 $36
2009-06-30 $18
2009-03-31 $22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00